The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 57 of the 178 sources its claims cite were checked for support.
Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review
Open accessAbstract
Background: Intraocular inflammation is an uncommon but potentially vision-threatening adverse event related to anti-VEGF therapy. This is of increasing importance given both the volume of injections performed, as well as the increased prevalence of inflammation seen with newer anti-VEGF agents. Brolucizumab, the newest anti-VEGF agent, has been associated with an inflammatory retinal vasculitis and the underlying mechanism is unclear. Reviewing potential mechanisms and clinical differences of intraocular inflammation may assist clinicians and scientists in reducing the risk of these events in the future. Observations: Two types of inflammation are seen with intravitreal injections, acute onset sterile inflammation and delayed onset inflammatory vasculitis. Acute onset inflammation can be subcategorized into subclinical anterior chamber inflammation and sterile uveitis/endophthalmitis. Subclinical anterior chamber inflammation can occur at rates as high as 19% after intravitreal anti-VEGF injection. Rates of sterile uveitis/endophthalmitis range from 0.05% to 4.4% depending on the anti-VEGF agent. Inflammatory vasculitis is only associated with brolucizumab and occurred in 3.3% of injections according to the post hoc review of the HAWK/HARRIER data. In addition, silicone oil from syringes can induce immunogenic protein aggregates. Agitation of the syringe, freeze thawing, shipping and improper storage prior to injection may increase the amount of silicone oil released from the syringe. Conclusion: The main factors which play a role in intraocular inflammation after anti-VEGF injection can be divided into three causes: patient-specific, medication-specific and delivery-specific. The majority of clinically significant inflammation seen after intravitreal injection is an acute onset inflammatory response with most patients recovering baseline VA in 3–5 weeks. The presence of pain, hypopyon, severe anterior chamber reaction, hyperemia and significant vision loss may help distinguish infectious from non-infectious etiologies of post injection inflammation. Avoiding temperature fluctuation, mechanical shock, agitation during transport and handling of syringes/drugs, and the use of SO-free syringes may help minimize intraocular inflammation. While a definitive mechanism has not yet been established, current knowledge of the clinical presentation and vitreous histopathology of brolucizumab-retinal vasculitis favors an auto-immune type IV hypersensitivity reaction.
Overview
CoChat Summary
TL;DR
This narrative review summarizes sterile intraocular inflammation after intravitreal anti-VEGF injection, dividing it into acute onset sterile inflammation and delayed onset inflammatory vasculitis. It highlights patient-, medication-, and delivery-specific factors, especially silicone oil/protein aggregation and brolucizumab-associated type IV hypersensitivity.
Key findings
- Acute onset sterile inflammation ranges from subclinical anterior chamber inflammation, reported as high as 19% after anti-VEGF injection, to sterile uveitis/endophthalmitis, with rates from 0.05% to 4.4% depending on the agent.
- Inflammatory vasculitis is associated only with brolucizumab in this review; post hoc HAWK/HARRIER review reported inflammation and concomitant retinal vasculitis in 3.3% and vascular occlusion in 2.1%, with about 22% of vasculitis patients losing >15 ETDRS letters.
- An ASRS retrospective series of 26 eyes found BCVA worsened from 20/52 at baseline to 20/151 at presentation, mean final BCVA 20/243, 46% with >3-line visual acuity decrease, and occlusive vasculitis in 85%.
- Silicone oil from syringes can induce immunogenic protein aggregates; agitation, freeze-thawing, shipping, and improper storage may increase silicone oil release, and avoiding syringe flicking and using SO-free syringes may reduce inflammation.
Methods
- Narrative review using PubMed to identify English-language articles published through March 25, 2021, with search terms including anti-VEGF, inflammation, sterile endophthalmitis, uveitis, intravitreal injections, and sterile inflammation.
- The final literature set comprised 84 articles; because of a lack of randomized clinical trials, the authors also included case reports, case series, and review articles.
- Titles and abstracts were reviewed for inclusion, and additional articles were identified from citations and similar PubMed papers; findings were synthesized narratively.
Limitations
- The paper states that randomized clinical trials were lacking, so case reports, case series, and review articles were included.
- The paper states that the small number and heterogeneity of brolucizumab-associated vasculitis cases made clarifying a causative factor difficult, and a definitive mechanism has not been established.
- Evident from the text: as a narrative review, it does not report a systematic quality appraisal or meta-analytic synthesis of the included evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
45 Valid · 11 Not valid · 63 Not checked · 51 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Clinical features and epidemiology of inflammation after antiangiogenic injection > Acute onset sterile inflammation
What the sources say
- Disputedcites [32] Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908. sourceExperimental — accuracy not yet measured
The Results, under Adverse Events (page not provided), report endophthalmitis after 0.04% of ranibizumab injections and 0.07% of bevacizumab injections, not 0.16% and 0.5%. The source is the comparison study described, but its reported rates differ from those attributed to it. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Average time to presentation was 53 days after the last brolucizumab injection (range 8–137 days).”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Clinical features and epidemiology of inflammation after antiangiogenic injection > Delayed onset inflammatory vasculitis
What the sources say
- Disputedcites [37] Witkin AJ, Hahn P, Murray TG, Arevalo JF, Blinder KJ, Choudhry N, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269–79. sourceExperimental — accuracy not yet measured
The Results (Demographics; page not provided) report a mean time to presentation of 26 days after the most recent brolucizumab injection (range 3–63 days). The 53-day mean and 8–137-day range appear in Results (Outcomes), but measure time from the last injection to the most recent follow-up visit, not to presentation. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Exposure to light has been shown to increase particulate count by 2.5 times [58].”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Putative causative factors of acute onset sterile inflammation > Silicone oil and protein aggregation
What the sources say
- Disputedcites [58] Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52(2):1023–34. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says light-exposed repackaged bevacizumab did not show a substantial increase in particles compared with samples kept from light. The controlled-study table reports counts of 213 ± 68 versus 108 ± 60 in one measure—about twofold, not 2.5-fold—and a lower count with light exposure in another measure. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Less commonly, corneal edema, conjunctival injection, ocular pain, photophobia, hypopyon, keratic precipitates, trabeculitis, retinal infiltrates and hemorrhages may occur [2, 11, 12, 14, 16–19].”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Clinical features and epidemiology of inflammation after antiangiogenic injection > Acute onset sterile inflammation
What the sources say
- Not checked — no full text of the sourcecites [2] Fine HF, Despotidis GD, Prenner JL. Ocular inflammation associated with antivascular endothelial growth factor treatment. Curr Opin Ophthalmol. 2015;26(3):184–7. source
- Not checked — no full text of the sourcecites [11] Greenberg JP, Belin P, Butler J, Feiler D, Mueller C, Tye A, et al. Aflibercept-related sterile intraocular inflammation outcomes. Ophthalmol Retina. 2019;3(9):753–9. source
- Not checked — no full text of the sourcecites [12] Williams PD, Chong D, Fuller T, Callanan D. Noninfectious vitritis after intravitreal injection of anti-vegf agents: variations in rates and presentation by medication. Retina. 2016;36(5):909–13. source
- Partly supportedcites [14] Kim JY, You YS, Kwon OW, Kim SH. Sterile inflammation after intravitreal injection of Aflibercept in a Korean population. Korean J Ophthalmol. 2015;29(5):325–30. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports pain and conjunctival injection in earlier series of sterile inflammation after aflibercept injection. The Results (page unavailable) report no pain or hypopyon in this paper’s four cases. Our copy does not document corneal edema, photophobia, keratic precipitates, trabeculitis, retinal infiltrates, or hemorrhages as features of these cases. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [16] Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93(4):457–62. source
- Not checked — no full text of the sourcecites [17] Kay CN, Tarantola RM, Gehrs KM, Folk JC, Mahajan VB, Boldt HC, et al. Uveitis following intravitreal bevacizumab: a non-infectious cluster. Ophthalmic Surg Lasers Imaging. 2011;42(4):292–6. source
- Not checked — no full text of the sourcecites [18] Mozayan A, Farah S. Acute anterior uveitis following intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2013;44(1):25–7. source
- Not checked — no full text of the sourcecites [19] Hahn P, Chung MM, Flynn HW Jr, Huang SS, Kim JE, Mahmoud TH, et al. Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA Ophthalmol. 2015;133(4):421–6. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Systemic or periocular steroids are rarely utilized [2, 11, 14, 23, 24].”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Clinical features and epidemiology of inflammation after antiangiogenic injection > Acute onset sterile inflammation
What the sources say
- Not checked — no full text of the sourcecites [2] Fine HF, Despotidis GD, Prenner JL. Ocular inflammation associated with antivascular endothelial growth factor treatment. Curr Opin Ophthalmol. 2015;26(3):184–7. source
- Not checked — no full text of the sourcecites [11] Greenberg JP, Belin P, Butler J, Feiler D, Mueller C, Tye A, et al. Aflibercept-related sterile intraocular inflammation outcomes. Ophthalmol Retina. 2019;3(9):753–9. source
- Partly supportedcites [14] Kim JY, You YS, Kwon OW, Kim SH. Sterile inflammation after intravitreal injection of Aflibercept in a Korean population. Korean J Ophthalmol. 2015;29(5):325–30. sourceExperimental — accuracy not yet measured
The Results (Case 2) describe oral prednisolone for one patient, while the Results summary reports topical steroid drops for three of the four cases. This small case series supports infrequent systemic steroid use in these aflibercept-associated cases, but it does not establish that systemic or periocular steroids are rarely used for sterile endophthalmitis generally. No page numbers are provided in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [23] Fine HF, Roth DB, Shah SP, Haque T, Wheatley HM. Frequency and characteristics of intraocular inflammation after aflibercept injection. Retina. 2015;35(4):681–6. source
- Not checked — no full text of the sourcecites [24] Trivizki O, Schwartz S, Negri N, Loewenstein A, Rabina G, Shulman S. Noninfectious inflammatory response following intravitreal bevacizumab injections: description of a cluster of cases in two centers and a review of the literature. Ophthalmologica. 2018;240(3):163–6. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
99 more claims · 30 with their cited sources checked
Create a free account to see all 170 claims and every source verdict.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 49
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Abstract > Observations
“Inflammatory vasculitis is only associated with brolucizumab and occurred in 3.3% of injections according to the post hoc review of the HAWK/HARRIER data.”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Clinical features and epidemiology of inflammation after antiangiogenic injection > Delayed onset inflammatory vasculitis
“Inflammatory vasculitis is only associated with brolucizumab and occurred in 3.3% of patients in the HAWK/HARRIER trials according to post hoc analysis [13].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Abstract > Observations
“Inflammatory vasculitis is only associated with brolucizumab and occurred in 3.3% of injections according to the post hoc review of the HAWK/HARRIER data.”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Clinical features and epidemiology of inflammation after antiangiogenic injection > Acute onset sterile inflammation
“This was mostly a mild to moderate uveitis/iritis, however 1.8% of patients developed retinal vasculitis [35].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Abstract > Observations
“Rates of sterile uveitis/endophthalmitis range from 0.05% to 4.4% depending on the anti-VEGF agent.”
§ Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review > Introduction
“The overall incidence of sterile intraocular inflammation mimicking uveitis/endophthalmitis post injection has varied widely in the literature, with ranges from 0.005%–4.4% [11–13].”
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells
Stevens, T. L., Bossie, A., Sanders, V. M., Fernandez-Botran, R., Coffman, R. L., Mosmann, T. R., & Vitetta, E. S. (1988) · Nature · doi:10.1038/334255a0 · Cited by 933
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Cited by
Microglia in retinal angiogenesis and diabetic retinopathy
Hu, A., Schmidt, M. H. H., & Heinig, N. (2024) · Angiogenesis · doi:10.1007/s10456-024-09911-1 · Cited by 118
Severe Intraocular Inflammation Following Intravitreal Faricimab
Thangamathesvaran, L., Kong, J., Bressler, S. B., Singh, M. S., Wenick, A. S., Scott, A. W., Arévalo, J. F., & Bressler, N. M. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.0530 · Cited by 68
Ma, P., Pan, X., Liu, R., Qu, Y., Xie, L., Xie, J., Cao, L., & Chen, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1017889 · Cited by 50
“In addition, protein aggregation or change in conformation may also cause endophthalmitis (Melo et al., 2019; Anderson et al., 2021; Melo et al., 2021), due to the delivery-specific constraints.”
BackgroundInfluentialSterile Intraocular Inflammation Associated With Faricimab
Cozzi, M., Ziegler, A., Fasler, K., Muth, D. R., Blaser, F., & Zweifel, S. A. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.3828 · Cited by 48
Bressler, N. M., Kim, T., Oh, I., Russo, P., Kim, M. Y., & Woo, S. J. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.5403 · Cited by 40
Metadata
- Authors
- Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B.
- Affiliations
- Saint Louis University (US)
- Universidade Federal de São Paulo (BR)
- The Retina Center (US)
- Corresponding author
- Melo, Gustavo Barreto
- Venue
- International Journal of Retina and Vitreous
- Published
- 2021-05-07
- Volume
- 7
- Issue
- 1
- Pages
- 37-37
- ISSN
- 2056-9920 (ISSN-L)
- PMC
- PMC8103589
- OpenAlex
- W3157686683
- Cited by
- 155
- References
- 82
- Citations by year
- 2026: 36 · 2025: 38 · 2024: 32 · 2023: 25 · 2022: 19 · 2021: 5
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- International Journal of Retina and Vitreous (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- sterile inflammation, intraocular inflammation, anti-VEGF therapy, intravitreal injection, brolucizumab, retinal vasculitis, endophthalmitis, silicone oil, delayed-type hypersensitivity, adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. https://app.cochat.ai/papers/10.1186/s40942-021-00307-7
- The paper
- Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021). Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. International Journal of Retina and Vitreous. https://doi.org/10.1186/s40942-021-00307-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.